Generic Sweden (GENI) Q3 2024 earnings summary

Executive summary

• Achieved record results in Q3 2024, with 24% revenue growth and highest-ever quarterly EBITDA above 9 MSEK.

• Signed 74 new customer agreements, mainly from existing clients, and saw strong demand for new SaaS product DOCS.

• Margins improved due to cost compensation and increased SaaS revenue share; operational costs have stabilized.

• All key verticals (e-commerce, healthcare, public safety) showed growth despite broader e-commerce sector slowdown.

• Positioned to lead innovation in business messaging with upcoming RCS technology launch.

Financial highlights

• Q3 2024 revenue rose 24% to 43.06 MSEK (34.72 MSEK); EBITDA up 13% to 9.09 MSEK (8.01 MSEK).

• EPS for Q3 was 0.58 SEK (0.51 SEK); operating cash flow reached 11.16 MSEK (3.83 MSEK).

• For Jan–Sep 2024, revenue increased 24% to 128.64 MSEK (103.95 MSEK); EBITDA up 2% to 23.20 MSEK (22.71 MSEK).

• Jan–Sep EPS was 1.47 SEK (1.44 SEK); operating cash flow 18.92 MSEK (15.15 MSEK).

• Q3 gross margin improved to just over 41%, with gross profit up 14% year-over-year.

Outlook and guidance

• Demand remains strong in core verticals; continued growth expected in Q4 2024.

• SaaS product DOCS shows high potential, with plans for broader distribution.

• RCS technology launch anticipated to open new business opportunities once technical prerequisites are met.